The independent platform for news, articles and advice for professionals in laboratory medicine

Expression of PRAME in melanocytic lesions: significance and evaluation

Immunohistochemistry is a vital tool in the classification of melanocytic skin lesions. Here, Karolina Wojcik and colleagues assess PRAME expression as a new marker in recognising and distinguishing the malignant melanomas from atypical naevi.

According to Cancer Research UK statistics,1 malignant melanoma is the fifth most common cancer in the UK, and each year around 16,000 people are diagnosed with this deadly skin cancer. Cutaneous melanocytic lesions can be divided into benign and atypical melanocytic naevi, and the most aggressive type of skin malignancy, malignant melanoma (MM).

                This study aims to evaluate the staining pattern of PRAME (PReferentially expressed Antigen in MElanoma) expression in melanocytic tumours, and highlights PRAME expression in primary and metastatic melanomas as well as other melanocytic lesions. This research looks at the potential to explore PRAME expression in melanocytic naevi, which could prove an invaluable input to distinguish the benign/atypical naevi from melanomas.

                PRAME is a melanoma-associated antigen first identified through analysis of the specificity of T-cell clones in a patient with metastatic melanoma. Using PRAME antibody in a diagnostic laboratory can prove to be an invaluable addition in the clinical setting, distinguishing benign and malignant melanocytic lesions.

Log in or register FREE to read the rest

This story is Premium Content and is only available to registered users. Please log in at the top of the page to view the full text. If you don't already have an account, please register with us completely free of charge.
Register

Upcoming Events

POCT Innovators: The Power to Disrupt Series

Cloth Hall Court, Leeds. UK
20 March, 2024

Interpreting Reports: UK NEQAS Haematology

ONLINE
21st March 2024

USCAP 113th Annual Meeting

Baltimore Convention Center, Baltimore, Maryland, USA
23-28 March, 2024

Pathology Horizons 2024

MacDonald Bath Spa Hotel, Bath
18-20 April, 2024

Diagnostics North East Conference 2024

The Catalyst, Newcastle upon Tyne
19 April, 2024

ECCMID 2024 - European Congress of Clinical Microbiology and Infectious Diseases

Fira Gran Via, 08038 Barcelona, Spain
27-30 April 2024

Access the latest issue of Pathology In Practice on your mobile device together with an archive of back issues.

Download the FREE Pathology In Practice app from your device's App store

Upcoming Events

POCT Innovators: The Power to Disrupt Series

Cloth Hall Court, Leeds. UK
20 March, 2024

Interpreting Reports: UK NEQAS Haematology

ONLINE
21st March 2024

USCAP 113th Annual Meeting

Baltimore Convention Center, Baltimore, Maryland, USA
23-28 March, 2024

Pathology Horizons 2024

MacDonald Bath Spa Hotel, Bath
18-20 April, 2024

Diagnostics North East Conference 2024

The Catalyst, Newcastle upon Tyne
19 April, 2024

ECCMID 2024 - European Congress of Clinical Microbiology and Infectious Diseases

Fira Gran Via, 08038 Barcelona, Spain
27-30 April 2024

Access the latest issue of Pathology In Practice on your mobile device together with an archive of back issues.

Download the FREE Pathology In Practice app from your device's App store

Step Communications Ltd, Step House, North Farm Road, Tunbridge Wells, Kent TN2 3DR
Tel: 01892 779999
www.step-communications.com
© 2024 Step Communications Ltd. Registered in England. Registration Number 3893025